-
Mashup Score: 0GSK drops one potential 'functional cure' for hep B as it goes all-in on bepirovirsen - 2 day(s) ago
GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential functional cure for the infectious disease. | GSK is prioritizing development of its hepatitis B treatment bepirovirsen, even as the pharma ends work on another potential functional cure for the infectious disease.
Source: www.fiercebiotech.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 1
Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 trial. | Shionogi’s respiratory syncytial virus antiviral for adults has proven its ability to reduce viral load in a phase 2 trial.
Source: www.fiercebiotech.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 3AI drug discoverer's antiviral reduces COVID in mouse lungs, neutralizes other RNA viruses - 10 day(s) ago
Many of the most devastating infectious diseases are caused by RNA viruses, and Model Medicines is working on one compound to kill them all. | Many of the most devastating infectious diseases are caused by RNA viruses, and Model Medicines is working on one compound to kill them all. The AI drug discoverer’s oral small molecule was able to reduce SARS-CoV levels in the lungs of infected mice and also neutralized other RNA viruses like hepatitis C, norovirus and flu in cultured cells.
Source: www.fiercebiotech.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 0
Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong,
Source: www.fiercebiotech.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 0Inflammatix collects FDA clearance for ER sepsis diagnostic test - 15 day(s) ago
Inflammatix has secured the FDA’s blessing for its in vitro diagnostic system, aimed at rapidly profiling the body’s response to an infectious disease at the point of care. | With results in about 30 minutes, the benchtop TriVerity test is designed to help emergency department clinicians determine whether a patient is fighting off a bacterial or viral infection, and to see if they may be at risk for developing sepsis.
Source: www.fiercebiotech.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2Inflammatix collects FDA clearance for ER sepsis diagnostic test - 16 day(s) ago
Inflammatix has secured the FDA’s blessing for its in vitro diagnostic system, aimed at rapidly profiling the body’s response to an infectious disease at the point of care. | With results in about 30 minutes, the benchtop TriVerity test is designed to help emergency department clinicians determine whether a patient is fighting off a bacterial or viral infection, and to see if they may be at risk for developing sepsis.
Source: www.fiercebiotech.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 2HHS gives Moderna $590M to 'accelerate' bird flu vaccine trials - 17 day(s) ago
The U.S. | The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains with pandemic potential.
Source: www.fiercebiotech.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 1JPM25: GE HealthCare, UCSF launch research hub for cancer, neurodegenerative disease imaging - 21 day(s) ago
SAN FRANCISCO—GE HealthCare is launching a new imaging research collaboration with the University of California, San Francisco, aimed at improving the diagnosis of neurodegenerative disea | The project will launch a Care Innovation Hub within UCSF’s Department of Radiology & Biomedical Imaging, to serve as a home that brings together the university’s oncology and brain research and GE HealthCare’s product development efforts.
Source: www.fiercebiotech.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
SAN FRANCISCO—In an early look at its annual earnings report, Guardant Health posted revenue gains of 31%—with the $737 million total topping not only Wall Street estimates, but its own f | In an early look at its 2024 earnings, Guardant’s $737 million total topped not only Wall Street estimates but its own financial forecast.
Source: www.fiercebiotech.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 4
Blueprint Medicines is cutti | Blueprint Medicines is cutting funding to its clinical-stage CDK2 inhibitor even as the Ayvakit-maker pushes forward with similar preclinical breast cancer-focused therapies.
Source: www.fiercebiotech.comCategories: General Medicine News, Hem/OncsTweet
“The reemphasis on bepirovirsen came as GSK disclosed this morning that it has discontinued work on GSK3528869. The company had been holding out hopes that the candidate could be another functional cure for the infection” https://t.co/RLej98JzMA